Details of the Drug Combinations

General Information of This Drug (ID: DMRD5SP)

Drug Name

Fenretinide DMRD5SP

Synonyms

RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR

Indication

Disease Entry	ICD 11	Status	REF
Macular degeneration	9B78.3	Phase 3	[1]
Lymphoma	2A80-2A86	Phase 2	[2]
Peripheral T-cell lymphoma	2A90.C	Phase 2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Tumour	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

11 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AS602868 + Fenretinide	DCAYKTD	AS602868	Glioblastoma (Cell Line: JHH-136)	[4]
Fenretinide + GDC0941	DC6VV5D	GDC0941	Glioblastoma (Cell Line: JHH-136)	[4]
Fenretinide + Cladribine	DCTKFH5	Cladribine	Glioblastoma (Cell Line: JHH-136)	[4]
Fenretinide + Carfilzomib	DC0YZL1	Carfilzomib	Glioblastoma (Cell Line: JHH-136)	[4]
Fenretinide + Ixazomib	DC4C0XI	Ixazomib	Glioblastoma (Cell Line: JHH-136)	[4]
Fenretinide + AZD8055	DCOIF0N	AZD8055	Glioblastoma (Cell Line: JHH-136)	[4]
Fenretinide + GDC-0980/RG7422	DCYVERR	GDC-0980/RG7422	Glioblastoma (Cell Line: JHH-136)	[4]
Fenretinide + OSI-027	DCPCRH8	OSI-027	Glioblastoma (Cell Line: JHH-136)	[4]
Fenretinide + Bardoxolone methyl	DCYC3V4	Bardoxolone methyl	Glioblastoma (Cell Line: JHH-136)	[4]
Topetecan + Fenretinide	DCNVG79	Topetecan	Glioblastoma (Cell Line: JHH-136)	[4]
Vorinostat + Fenretinide	DCV3BT9	Vorinostat	Glioblastoma (Cell Line: JHH-136)	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 DrugCom(s)

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Lonafarnib + Fenretinide	DCZCUK5	Lonafarnib	Head and Neck Cancer	[5]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00003075) Fenretinide in Treating Patients With Cervical Neoplasia. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	ClinicalTrials.gov (NCT00102635) 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)